Clinical Trials Logo

Neutropenia, Malignant clinical trials

View clinical trials related to Neutropenia, Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT03314805 Completed - Clinical trials for Cancer-related Fatigue

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Start date: March 1, 2018
Phase: Phase 2
Study type: Interventional

Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.